Lung Cancer | Norton Healthcare

Indication: Lung Cancer

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Sub-indication: Non-Small Cell Lung Cancer

Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: Merck Sharp & Dohme CORP

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.